Time's up: the urgency to investigate time toxicity in patients with genitourinary malignancies.

IF 4.3 2区 医学 Q2 ONCOLOGY Therapeutic Advances in Medical Oncology Pub Date : 2024-12-11 eCollection Date: 2024-01-01 DOI:10.1177/17588359241305088
Daniel Sentana-Lledo, Alicia K Morgans
{"title":"Time's up: the urgency to investigate time toxicity in patients with genitourinary malignancies.","authors":"Daniel Sentana-Lledo, Alicia K Morgans","doi":"10.1177/17588359241305088","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with genitourinary (GU) malignancies have seen the development of multiple life-prolonging treatments in the past decade. As patients and clinicians consider their treatment options along the cancer journey, time spent with healthcare contact, or \"time toxicity,\" has emerged as a new outcome measure that comprehensively considers time receiving cancer care, including planned visits for evaluation and treatment as well as unplanned urgent care addressing complications. Despite its rising study across cancer populations, there has been a surprising lack of work evaluating time toxicity in patients with GU cancers. This narrative review aims to summarize the available studies on time toxicity in cancer, with a deeper dive into the methodology, strengths and limitations, and future directions of the field. A dedicated section focused on scenarios and best practices to measure and collect data on time toxicity can serve to spark interest in evaluating this novel health outcome on GU cancer survivors. Ultimately, time toxicity is a relevant patient-centered metric that can be incorporated into clinical trial design and routine clinical care to influence clinical decision-making.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241305088"},"PeriodicalIF":4.3000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632889/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241305088","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with genitourinary (GU) malignancies have seen the development of multiple life-prolonging treatments in the past decade. As patients and clinicians consider their treatment options along the cancer journey, time spent with healthcare contact, or "time toxicity," has emerged as a new outcome measure that comprehensively considers time receiving cancer care, including planned visits for evaluation and treatment as well as unplanned urgent care addressing complications. Despite its rising study across cancer populations, there has been a surprising lack of work evaluating time toxicity in patients with GU cancers. This narrative review aims to summarize the available studies on time toxicity in cancer, with a deeper dive into the methodology, strengths and limitations, and future directions of the field. A dedicated section focused on scenarios and best practices to measure and collect data on time toxicity can serve to spark interest in evaluating this novel health outcome on GU cancer survivors. Ultimately, time toxicity is a relevant patient-centered metric that can be incorporated into clinical trial design and routine clinical care to influence clinical decision-making.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
时间到了:研究泌尿生殖系统恶性肿瘤患者时间毒性的紧迫性。
泌尿生殖系统(GU)恶性肿瘤患者在过去十年中已经看到了多种延长生命治疗的发展。随着患者和临床医生在癌症治疗过程中考虑他们的治疗方案,与医疗保健联系的时间,或“时间毒性”,已经成为一种新的结果衡量标准,它综合考虑了接受癌症治疗的时间,包括计划中的评估和治疗访问,以及针对并发症的计划外紧急护理。尽管对癌症人群的研究越来越多,但对GU癌症患者的时间毒性评估的工作却令人惊讶地缺乏。这篇叙述性综述旨在总结癌症时间毒性的现有研究,深入探讨该领域的方法、优势和局限性以及未来的发展方向。一个专门的章节侧重于测量和收集时间毒性数据的情景和最佳做法,可以激发人们对评估GU癌症幸存者这一新的健康结果的兴趣。最终,时间毒性是一个以患者为中心的相关指标,可以纳入临床试验设计和常规临床护理,以影响临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.20
自引率
2.00%
发文量
160
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
期刊最新文献
Efficacy and safety of immunotherapy in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: a multicenter retrospective study. Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. Rare epithelial gastric cancers: a review of the current treatment knowledge. The association between level IV/V metastasis and the recurrence, distant metastasis, and survival outcomes in hypopharyngeal squamous cell carcinoma. Extracellular vesicles-a new player in the development of urinary bladder cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1